Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Short term Debt: 2011-2022

Historic Short term Debt for Ligand Pharmaceuticals (LGND) over the last 6 years, with Dec 2022 value amounting to $76.7 million.

  • Ligand Pharmaceuticals' Short term Debt was N/A to $76.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $76.8 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2022, which is N/A change from last year.
  • Ligand Pharmaceuticals' Short term Debt amounted to $76.7 million in FY2022, which was up 190.15% from $26.4 million recorded in FY2018.
  • In the past 5 years, Ligand Pharmaceuticals' Short term Debt registered a high of $76.7 million during FY2022, and its lowest value of $26.4 million during FY2018.
  • Over the past 1 years, Ligand Pharmaceuticals' median Short term Debt value was $76.7 million (recorded in 2022), while the average stood at $76.7 million.
  • Data for Ligand Pharmaceuticals' Short term Debt shows a maximum YoY plummeted of 88.23% (in 2018) over the last 5 years.
  • Yearly analysis of 2 years shows Ligand Pharmaceuticals' Short term Debt stood at $26.4 million in 2018, then followed by $76.7 million in 2022.